Cramer’s Investing Club: Buy Eli Lilly’s drop on drug delay news

We see the pushback of donanemab’s accelerated approval submission as just a speed bump.



Read More: Cramer’s Investing Club: Buy Eli Lilly’s drop on drug delay news